Structure via PubChem · Public domain (PubChem)
topiroxostat
Sign in to saveAlso known as C13H8N6, 4-(5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl)pyridine-2-carbonitrile
Topiroxostat (INN; trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia. It was approved for use in Japan in June 2013.
Chemical data
- Formula
- C13H8N6
- Molecular weight
- 248.24 g/mol
- IUPAC name
- 4-(5-pyridin-4-yl-1H-1,2,4-triazol-3-yl)pyridine-2-carbonitrile
- SMILES
- C1=CN=CC=C1C2=NC(=NN2)C3=CC(=NC=C3)C#N
- InChIKey
- UBVZQGOVTLIHLH-UHFFFAOYSA-N
- XLogP
- 1.2
- Polar surface area
- 91.1 Ų
- H-bond donors
- 1
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- diabetic nephropathy, hyperuricemia
via ChEMBL · EBI
Research
139 papers- Topiroxostat-A Safer Uricostatic Drug with Enhanced Renal Protection: A Narrative Review.The Journal of the Association of Physicians of India · 2024
- Topiroxostat ameliorates oxidative stress and inflammation in sepsis-induced lung injury.Zeitschrift fur Naturforschung. C, Journal of biosciences · 2020
- Topiroxostat improves glomerulosclerosis in type 2 diabetic Nagoya Shibata Yasuda mice with early diabetic kidney disease.European journal of pharmacology · 2024
- Protective Effect of Topiroxostat on Myocardial Injury Induced by Lipopolysaccharide.The Journal of surgical research · 2022
- Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial.PloS one · 2022
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 248.081
Show 3 more facts
- chemical formula
- C₁₃H₈N₆
- canonical SMILES
- C1=CN=CC=C1C2=NC(=NN2)C3=CC(=NC=C3)C#N
- subject has role
- xanthine oxidase inhibitor
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Topiroxostat (INN; trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia. It was approved for use in Japan in June 2013.
Topiroxostat is a xanthine oxidase inhibitor which reduces serum urate levels.
Excerpted from Wikipedia’s “topiroxostat” article, available under the CC BY-SA 4.0 licence.